Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I (original) (raw)
Journal Article
,
Search for other works by this author on:
,
Search for other works by this author on:
,
Search for other works by this author on:
,
Search for other works by this author on:
,
Search for other works by this author on:
,
Search for other works by this author on:
,
Search for other works by this author on:
,
Search for other works by this author on:
,
Search for other works by this author on:
,
Search for other works by this author on:
Published:
01 November 2008
Cite
Antonella Meloni, Maria Furcas, Filomena Cetani, Claudio Marcocci, Alberto Falorni, Roberto Perniola, Mikuláš Pura, Anette S. Bøe Wolff, Eystein S. Husebye, Desa Lilic, Kelli R. Ryan, Andrew R. Gennery, Andrew J. Cant, Mario Abinun, Gavin P. Spickett, Peter D. Arkwright, David Denning, Colm Costigan, Maria Dominguez, Vivienne McConnell, Nick Willcox, Anthony Meager, Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I, The Journal of Clinical Endocrinology & Metabolism, Volume 93, Issue 11, 1 November 2008, Pages 4389–4397, https://doi.org/10.1210/jc.2008-0935
Close
Navbar Search Filter Mobile Enter search term Search
Context: In autoimmune polyendocrinopathy syndrome type I (APS-I), mutations in the autoimmune regulator gene (AIRE) impair thymic self-tolerance induction in developing T cells. The ensuing autoimmunity particularly targets ectodermal and endocrine tissues, but chronic candidiasis usually comes first. We recently reported apparently APS-I-specific high-titer neutralizing autoantibodies against type I interferons in 100% of Finnish and Norwegian patients, mainly with two prevalent AIRE truncations.
Objectives: Because variability in clinical features and age at onset in APS-I frequently results in unusual presentations, we prospectively checked the diagnostic potential of anti-interferon antibodies in additional APS-I panels with other truncations or rare missense mutations and in disease controls with chronic mucocutaneous candidiasis (CMC) but without either common AIRE mutation.
Design: The study was designed to detect autoantibodies against interferon-α2 and interferon-ω in antiviral neutralization assays.
Setting and Patients: Patients included 14 British/Irish, 15 Sardinian, and 10 Southern Italian _AIRE_-mutant patients with APS-I; also 19 other patients with CMC, including four families with cosegregating thyroid autoimmunity.
Outcome: The diagnostic value of anti-interferon autoantibodies was assessed.
Results: We found antibodies against interferon-α2 and/or interferon-ω in all 39 APS-I patients vs. zero of 48 unaffected relatives and zero of 19 British/Irish CMC patients. Especially against interferon-ω, titers were nearly always high, regardless of the exact APS-I phenotype/duration or AIRE genotype, including 12 different AIRE length variants or 10 point substitutions overall (n = 174 total). Strikingly, in one family with few typical APS-I features, these antibodies cosegregated over three generations with autoimmune hypothyroidism plus a dominant-negative G228W AIRE substitution.
Conclusions: Otherwise restricted to patients with thymoma and/or myasthenia gravis, these precocious persistent antibodies show 98% or higher sensitivity and APS-I specificity and are thus a simpler diagnostic option than detecting AIRE mutations.
Copyright © 2008 by The Endocrine Society
You do not currently have access to this article.
Personal account
- Sign in with email/username & password
- Get email alerts
- Save searches
- Purchase content
- Activate your purchase/trial code
- Add your ORCID iD
Get help with access
Institutional access
Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:
IP based access
Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.
Sign in through your institution
Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.
- Click Sign in through your institution.
- Select your institution from the list provided, which will take you to your institution's website to sign in.
- When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
- Following successful sign in, you will be returned to Oxford Academic.
If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.
Sign in with a library card
Enter your library card number to sign in. If you cannot sign in, please contact your librarian.
Society Members
Society member access to a journal is achieved in one of the following ways:
Sign in through society site
Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:
- Click Sign in through society site.
- When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
- Following successful sign in, you will be returned to Oxford Academic.
If you do not have a society account or have forgotten your username or password, please contact your society.
Sign in using a personal account
Some societies use Oxford Academic personal accounts to provide access to their members. See below.
Personal account
A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.
Some societies use Oxford Academic personal accounts to provide access to their members.
Viewing your signed in accounts
Click the account icon in the top right to:
- View your signed in personal account and access account management features.
- View the institutional accounts that are providing access.
Signed in but can't access content
Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.
Institutional account management
For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.
Purchase
Short-term Access
To purchase short-term access, please sign in to your personal account above.
Don't already have a personal account? Register
Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I - 24 Hours access
EUR €38.00
GBP £33.00
USD $41.00
Rental
This article is also available for rental through DeepDyve.
Citations
Views
Altmetric
Metrics
Total Views 2,558
1,949 Pageviews
609 PDF Downloads
Since 1/1/2017
Month: | Total Views: |
---|---|
January 2017 | 1 |
February 2017 | 5 |
March 2017 | 3 |
April 2017 | 3 |
May 2017 | 8 |
June 2017 | 4 |
July 2017 | 8 |
August 2017 | 8 |
September 2017 | 10 |
October 2017 | 6 |
November 2017 | 5 |
December 2017 | 16 |
January 2018 | 25 |
February 2018 | 20 |
March 2018 | 9 |
April 2018 | 30 |
May 2018 | 15 |
June 2018 | 34 |
July 2018 | 34 |
August 2018 | 39 |
September 2018 | 63 |
October 2018 | 24 |
November 2018 | 50 |
December 2018 | 44 |
January 2019 | 35 |
February 2019 | 27 |
March 2019 | 47 |
April 2019 | 44 |
May 2019 | 26 |
June 2019 | 25 |
July 2019 | 34 |
August 2019 | 15 |
September 2019 | 32 |
October 2019 | 13 |
November 2019 | 15 |
December 2019 | 16 |
January 2020 | 14 |
February 2020 | 15 |
March 2020 | 24 |
April 2020 | 13 |
May 2020 | 15 |
June 2020 | 35 |
July 2020 | 25 |
August 2020 | 14 |
September 2020 | 48 |
October 2020 | 61 |
November 2020 | 60 |
December 2020 | 41 |
January 2021 | 53 |
February 2021 | 47 |
March 2021 | 51 |
April 2021 | 32 |
May 2021 | 32 |
June 2021 | 30 |
July 2021 | 34 |
August 2021 | 26 |
September 2021 | 60 |
October 2021 | 36 |
November 2021 | 28 |
December 2021 | 20 |
January 2022 | 31 |
February 2022 | 30 |
March 2022 | 27 |
April 2022 | 42 |
May 2022 | 20 |
June 2022 | 21 |
July 2022 | 23 |
August 2022 | 25 |
September 2022 | 47 |
October 2022 | 72 |
November 2022 | 26 |
December 2022 | 47 |
January 2023 | 40 |
February 2023 | 9 |
March 2023 | 27 |
April 2023 | 51 |
May 2023 | 42 |
June 2023 | 7 |
July 2023 | 15 |
August 2023 | 23 |
September 2023 | 14 |
October 2023 | 18 |
November 2023 | 15 |
December 2023 | 12 |
January 2024 | 35 |
February 2024 | 35 |
March 2024 | 37 |
April 2024 | 46 |
May 2024 | 35 |
June 2024 | 19 |
July 2024 | 23 |
August 2024 | 22 |
September 2024 | 11 |
October 2024 | 4 |
Citations
125 Web of Science
×
Email alerts
Related articles in PubMed
Citing articles via
More from Oxford Academic